查看文章

Benign Prostatic Hyperplasia (BPH) is a common progressive disease among men, with an incidence that is high among elderly. Velvanga parpam (VP) has been employed as traditional remedy for Benign Prostatic Hyperplasia (BPH) which is a herbo mineral formulation. As a mandate, steps were taken to evaluate safety profile of VP in rats and mice following OECD guidelines. Acute toxicity studies, different doses of VP were administered orally to rats once daily for one week. Sub-acute toxicity studies were carried in four different groups in which VP was administrated orally to rats once daily for 28 days in various doses ranging from 2.5, 5, 10 Mg/kg for mice respectively. Detailed hematological, biochemical, necropsy and histopathological evaluation of organs was performed for all animals. The VP was well tolerated and no toxic manifestations were seen in any animal. Histopathological analysis revealed that Spleen, Testes, Pancreas, Lung, Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues of treated groups did not show any signs of toxicity. Mortality observed in highdose. The VP was found to be safe in animals. No toxic effect was observed up to 5mg/kg of Velvanga parpam in acute and sub-acute toxicity studies.

INTRODUCTION: Benign Prostatic Hyperplasia (BPH) is a common progressive disease among men, with an incidence that is high among elderly. Histological BPH, which typically develops after the age of 40 years, ranges in prevalence from 50% at 60 years to as high as 90% by 85 years of age 1-3.